LegoChem Biosciences, Inc.
KOSDAQ 141080.KQ
LegoChem Biosciences, Inc. Price to Book Ratio (P/B) on January 14, 2025: 25.34
-
LegoChem Biosciences, Inc. 52-week high Price to Book Ratio (P/B) is 39.48 on November 12, 2024, which is 55.83% above the current Price to Book Ratio (P/B).
-
LegoChem Biosciences, Inc. 52-week low Price to Book Ratio (P/B) is 11.09 on February 05, 2024, which is -56.21% below the current Price to Book Ratio (P/B).
-
LegoChem Biosciences, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 19.40.
| Date | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield | Price to Earnings Ratio (P/E) |
|---|
| CEO | Mr. Yong Zu Kim Ph.D. |
| IPO Date | May 10, 2013 |
| Location | |
| Headquarters | 10, Gukjegwahak 10-ro |
| Employees | 157 |
| Sector | Health Care |
| Industries | |
LegoChem Biosciences, Inc. a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, and oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It offers its products in the forms of tablets and capsules. The Company also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. LegoChem Biosciences, Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email